Lenacapavir Tablet

DRUG6 trials

Sponsors

Gilead Sciences

Conditions

HIV InfectionsHIV Pre-exposure ProphylaxisHIV-1 InfectionPre-Exposure Prophylaxis of HIV Infection

Phase 2

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

Active, not recruitingNCT05729568

Gilead SciencesHIV-1 Infection

Start: 2023-05-15End: 2030-12-01Updated: 2026-04-27

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

Active, not recruitingNCT06101329

Gilead SciencesPre-Exposure Prophylaxis of HIV Infection

Start: 2023-11-17End: 2028-01-31Updated: 2025-09-23

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

Active, not recruitingNCT06101342

Gilead SciencesPre-Exposure Prophylaxis of HIV Infection

Start: 2023-12-13End: 2028-01-01Updated: 2026-03-02

Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)

Active, not recruitingNCT06513312

Gilead SciencesPre-Exposure Prophylaxis of HIV Infection

Start: 2024-10-07End: 2028-11-01Updated: 2026-05-19

Phase 3

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)

RecruitingNCT07047716

Gilead SciencesHIV Pre-exposure Prophylaxis

Start: 2025-07-22End: 2028-09-01Target: 350Updated: 2026-03-04

Unknown Phase

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

RecruitingNCT07473778

Gilead SciencesHIV Infections

Start: 2026-03-17End: 2029-04-01Target: 3000Updated: 2026-05-04

Related Papers

Methamphetamine use and HIV prevention: a qualitative study on challenges and opportunities for PrEP utilization.

2026-01-07

P-1248. Phase 2 Pharmacokinetics and Anti-Drug Antibody Results of the Investigational Twice-Yearly HIV-1 Treatment Regimen Lenacapavir, Teropavimab, and Zinlirvimab

Open Forum Infectious Diseases2026-01-01

P-365. Pooled safety and tolerability of twice-yearly lenacapavir with teropavimab and zinlirvimab for HIV-1 treatment

Open Forum Infectious Diseases2026-01-01